Vitamin C Supplementation Plus Hypoglycemic Agents Versus Hypoglycemic Agents Alone in Type 2 Diabetes Mellitus (Vit C)
Recruitment status was: Recruiting
No significant effect of vitamin C 500 mg Supplementation on the severity of micro-vascular complications of type 2 Diabetes Mellitus (DM).
There is a significant effect of vitamin C 500mg supplementation on the severity of the micro-vascular complications of type 2DM.
|Type 2 Diabetes Mellitus||Dietary Supplement: Vitamin C Drug: glyburide||Phase 1|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
|Official Title:||Phase 1 Study of Randomized Clinical Trial Comparing Vitamin C Supplementation Plus Oral Hypoglycemic Drugs Versus Hypoglycemic Drugs Alone on Serum Selenium, Zinc, Copper and Malondialdehyde Levels in Type 2 Diabetes Mellitus and Its Microvascular Complications|
- improving the renal function [ Time Frame: the renal function will be measure at day 1 and after one month ]vitamin c supplementation act as an antioxidants which reduce the oxidative stress and then can improve the renal function.
- Vitamin C can improve the visual fields [ Time Frame: the visual field will be assesed at day 1 and after one month ]the damage of the eye can be prevented by decreasing the oxidative stress in the eye, this can be accomplished by vitamin C.
|Study Start Date:||February 2011|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Experimental: Vitamin C supplementation plus oral hypoglycemic agents arm
This group will receive vitamin C supplementation 500mg daily for one month and then assessment will done for the patients.
Dietary Supplement: Vitamin C
Vitamin C supplementation 500mg
Active Comparator: Type 2DM patients receiving oral hypoglycemic agents alone
this group is the control group who receive oral hypoglycemic agents alone
this group receiving glyburide 5 mg alone
Please refer to this study by its ClinicalTrials.gov identifier: NCT01319734
|Contact: Hamdan Z Hamdan, MBBS, Mscemail@example.com|
|Contact: Maha I Mohammed, MBBS, PhD||+249912230895|
|Jaber abo aliz||Recruiting|
|Khartoum, Sudan, 1111|
|Contact: Khaled H Bakheet, MD,PhD +249912957764 firstname.lastname@example.org|
|Principal Investigator: Hamdan Z Hamdan, MBBS,MSc|
|Principal Investigator:||Hamdan Z Hamdan, MBBS, MSc||Al-Neelain University|